Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 9Carcinoma, Non-Small-Cell Lung 6Recurrence 5Hematologic Neoplasms 5Breast Neoplasms 5Neoplasm Metastasis 4Advanced Solid Tumors 4Solid Tumor 3Melanoma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myeloid, Acute 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neutropenia 2Medical Oncology 2Lymphoma, Follicular 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Biliary Tract Neoplasms 2Tuberous Sclerosis 1Solid Tumours 1Solid Tumour 1Solid Tumors 1Solid Tumor, Adult 1

Interventions

Rituximab 82venetoclax 56ibrutinib 46obinutuzumab 43Bendamustine Hydrochloride 40idelalisib 30Cyclophosphamide 29acalabrutinib 28fludarabine 27Chlorambucil 27pirtobrutinib 18ublituximab 16ofatumumab 16zanubrutinib 14umbralisib 14Lenalidomide 11fludarabine phosphate 9Alemtuzumab 9navitoclax 7duvelisib 7Azacitidine 5lumiliximab 4aflibercept 4TRU 016 4Interleukin-2 4BI 836826 4ARQ531 4tafasitamab 3motexafin gadolinium 3dinaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Lymphocytic, Chronic, B-Cell × Itraconazole × Clear all
NCT06787131 2025-12-05

Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers

Lomond Therapeutics Holdings, Inc.

Phase 1 Completed
104 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡